Company Overview of Eleven Biotherapeutics, Inc.
Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its product candidates include EBI-005, a novel interleukin-1 receptor antagonist that is in Phase III clinical program for the treatment of moderate to severe dry eye diseases; and has completed Phase II clinical trial for the treatment of allergic conjunctivitis. The company’s preclinical product candidates comprise EBI-031, a novel inhibitor of the cytokine interleukin-6 for the treatment of retinal dis...
215 First Street
Cambridge, MA 02142
Founded in 2008
Key Executives for Eleven Biotherapeutics, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $570.9K
Chief Development Officer
Total Annual Compensation: $198.0K
Chief Scientific Officer
Total Annual Compensation: $402.4K
Compensation as of Fiscal Year 2014.
Eleven Biotherapeutics, Inc. Key Developments
Eleven Biotherapeutics, Inc.(NasdaqGM:EBIO) dropped from Russell 2000 Index
Jun 29 15
Eleven Biotherapeutics, Inc. will be removed from Russell 2000 Index
Eleven Biotherapeutics, Inc.(NasdaqGM:EBIO) dropped from Russell 3000 Index
Jun 29 15
Eleven Biotherapeutics, Inc. will be removed from the Russell 3000 Index.
Eleven Biotherapeutics, Inc. Announces Executive Changes, Effective July 3, 2015
Jun 24 15
Eleven Biotherapeutics, Inc. announced that Gregory D. Perry has resigned as Chief Financial and Business Officer, effective July 3, 2015. John J. McCabe, Eleven’s Vice President of Finance and Business Operations, is promoted to assume the roles of Principal Financial Officer and Principal Accounting Officer, reporting directly to Abbie Celniker, PhD, President and Chief Executive Officer of Eleven Biotherapeutics. John McCabe has served as Vice President of Finance and Business Operations of Eleven since June 2013 and as Treasurer since September 2012. Prior to joining Eleven, Mr. McCabe was Vice President of Finance at Clinical Data, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 25, 2014
Most Searched Private Companies
Sponsored Financial Commentaries